Jubilant Pharmova Ltd (BSE: 530019) is a Noida, Uttar Pradesh-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹14,958 Cr, it ranks #460 by market cap among the 6,137 Indian listed companies on FinBizNet, and #7 of 11 in Pharmaceutical CDMO and CRO Services. At ₹938.30 (as of 25 Oct 2026), the share price is 20.7% below its 52-week high of ₹1,183.00 and 19.4% above its 52-week low of ₹786.05. The share price is down 12.8% over one year and down 2.8% over three months.
| Current Price | ₹938.30 |
|---|---|
| Market Cap | ₹14,958 Cr |
| BSE Code | 530019 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 37.3 |
| Return on Equity | 5.96% |
| Return on Assets | 3.62% |
| 52-Week Range | ₹786.05 – ₹1,183.00 |
| 1-Year Price Change | -12.8% |
| 3-Month Price Change | -2.8% |
| Beta (1Y) | 0.33 |
| Dividend Yield | 0.53% |
| Headquarters | Noida, Uttar Pradesh |
| Website | www.jubilantpharmova.com |
| Revenue | ₹2,229 Cr |
|---|---|
| Net Profit | ₹56 Cr |
| Net Margin | 2.5% |
| EPS (Basic) | ₹3.57 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distr
1. Pharmaceuticals (Excluding Drug Discovery and Development Solutions)-This segment offers specialty pharmaceuticals, including radiopharmaceuticals and allergy therapy products; contract development and manufacturing services; generics, such as solid dosage formulations; and India branded pharmaceuticals. 2. Contract Research and Development Services (Excl. Proprietary Novel Drugs)-This segment offers drug discovery and development services, as well as clinical data software and service solutions. 3. Proprietary Novel Drugs-This segment offers biopharmaceutical products to address oncology and autoimmune diseases. 4. Inter-Segment Revenue-0
1. Radio Pharma-44.6% 2. Allergy Immunotherapy-9.6% 3. Contract Development and Manufacturing Organization - Sterile Injectables-21.9% 4. Contract Research, Development and Manufacturing Organization-15.3% 5. Generics-9.3% 7. Unallocable Corporate-0.7%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹2,42,758 Cr | 93.8 | 16.19% | ₹3,080 Cr | +35.6% |
| Anthem Biosciences Limited | ₹46,303 Cr | 77.5 | 19.45% | ₹418 Cr | +5.3% |
| Sai Life Sciences Limited | ₹29,513 Cr | 85 | 15.13% | ₹554 Cr | +58.5% |
| Cohance Lifesciences Ltd | ₹17,754 Cr | 97.9 | 5.11% | ₹422 Cr | -49.9% |
| Onesource Specialty Pharma Limited | ₹16,144 Cr | -213 | -1.26% | ₹449 Cr | -27.8% |
| Syngene International Ltd. | ₹15,371 Cr | 50.6 | 6.62% | ₹736 Cr | -42.7% |
| Jubilant Pharmova Ltd | ₹14,958 Cr | 37.3 | 5.96% | ₹2,229 Cr | -12.8% |
| Concord Biotech Ltd | ₹14,008 Cr | 51.7 | 13.54% | ₹257 Cr | -19.5% |
| Blue Jet Healthcare Ltd | ₹9,855 Cr | 35.5 | 19.88% | ₹293 Cr | -29.2% |
Listed by market capitalisation. Ratios are shown for context only.
Jubilant Pharmova Ltd is trading at ₹938.30, with a market capitalisation of ₹14,958 Cr.
Jubilant Pharmova Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Jubilant Pharmova Ltd has a P/E of 37.3 and a return on equity of 5.96%.
Jubilant Pharmova Ltd is listed on the BSE under the scrip code 530019.
Jubilant Pharmova Ltd's share price is down 12.8% over one year and down 2.8% over three months. Its 52-week range is ₹786.05 to ₹1,183.00.
In Q1 FY27, Jubilant Pharmova Ltd reported revenue of ₹2,229 Cr and net profit of ₹56 Cr, with basic EPS of ₹3.57 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.